Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.

about

Respiratory syncytial virus seasonality and its implications on prevention strategies.Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value.

P2860

Q45323940-FEF8DC76-CE24-460E-A177-215FA2739E2F Q51411926-75E6628D-8A11-4FD3-AC10-1456BB3E4CA0

P2860

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.

Item

http://www.wikidata.org/entity/Q49720574

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Assessing Variation in the Cos ...... Prevention in Preterm Infants.

@en

Assessing Variation in the Cos ...... Prevention in Preterm Infants.

@nl

type

Item

label

Assessing Variation in the Cos ...... Prevention in Preterm Infants.

@en

Assessing Variation in the Cos ...... Prevention in Preterm Infants.

@nl

prefLabel

Assessing Variation in the Cos ...... Prevention in Preterm Infants.

@en

Assessing Variation in the Cos ...... Prevention in Preterm Infants.

@nl

P1476

Assessing Variation in the Cos ...... Prevention in Preterm Infants.

@en

P2093

Ahva Shahabi

http://www.w3.org/2001/XMLSchema#string

Desi Peneva

http://www.w3.org/2001/XMLSchema#string

Devin Incerti

http://www.w3.org/2001/XMLSchema#string

Kimmie McLaurin

http://www.w3.org/2001/XMLSchema#string

Warren Stevens

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application.

Persistent wandering atrial pacemaker after epinephrine overdosing - a case report.

Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study.

Heterogeneity in action: the role of passive personalization in comparative effectiveness research.

Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection

Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains

P2888

s41669-017-0042-3

P304

53-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S41669-017-0042-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29464672

http://www.w3.org/2001/XMLSchema#string

P921

preterm infant

P932

5820240

http://www.w3.org/2001/XMLSchema#string

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.

about

P2860

P2860

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P932